Jonathan Wesley Riess, M.D., M.S.
Director, Thoracic Oncology
Associate Professor of Medicine (Clin X)
To see if Jonathan Wesley Riess is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Department
Locations and Contact
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
Additional Numbers
Clinic Fax
Clinic Referral Phone
Physician Referrals
Philosophy of Care
Dr. Riess seeks to deliver exceptional clinical care by leveraging advances at UC Davis in novel diagnostics, targeted therapies and immunotherapy, while providing effective symptom management with a holistic approach towards patient care. Dr. Riess believes in high quality, innovative, and compassionate care of his patients. Dr. Riess believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for his patients.
Clinical Interests
Dr. Riess is Medical Director of Thoracic Oncology. Dr. Riess' clinical interests include lung cancer and other thoracic cancers (mesothelioma and thymoma) as well as head and neck cancers. He currently serves on the Non-Small Cell Lung Cancer/Malignant Pleural Mesothelioma/Thymomas and Thymic Carcinomas Panel for the National Comprehensive Cancer Network (NCCN). Dr. Riess seeks to deliver exceptional clinical care by leveraging advances at UC Davis in novel diagnostics, targeted therapies and immunotherapy, while providing effective symptom management with a holistic approach towards patient care.
Research/Academic Interests
Dr. Riess' research interests encompass novel diagnostics, targeted therapies and immunotherapies in lung cancer and other thoracic malignancies. He is the past recipient of the National Cancer Institute Cancer Clinical Investigator Team Leadership Award given to researchers who are working to improve the lives of people with cancer through extensive involvement in NCI-funded collaborative clinical trials and whose leadership, participation and activities promote clinical trials and research. He is also the past (co)recipient of the Addario Lung Cancer Foundation and Van Auken Foundation Young Innovators Team Award.
Division
Hematology and Oncology
Center/Program Affiliation
Undergraduate School
B.A., Psychobiology, Swarthmore College, Swarthmore PA 2000
Medical School
M.D., Robert Wood Johnson Medical School, Camden NJ 2006
Other School
M.S., Epidemiology and Clinical Research, Stanford University, Stanford CA 2013
Internship
Internal Medicine, UC San Francisco, San Francisco CA 2007
Residency
Internal Medicine, UC San Francisco, San Francisco CA 2006-2009
Fellowship
Hematology/Oncology, Stanford University School of Medicine, Stanford CA 2009-2011
Adi Gazdar Translational Research Lectureship Award. 17th World Conference on Lung Cancer. Vienna, Austria, 2016
Addario Lung Cancer Foundation and Van Auken Foundation Young Innovator in Lung Cancer, 2014
NIH K12 Career Development Award. UC Davis School of Medicine, 2013
Stanford Cancer Institute Developmental Cancer Research Award (with Joel Neal, MD, Ph.D.), 2012
NIH KL2 Clinical Research Scholar Award Recipient. Stanford University School of Medicine, 2011
For a comprehensive list of Riess' publications, please click here.
Levy B, Barlesi F, Paz-Ares L, Bennouna J, Erman M, Felip E, Isla D, Ryun Kim H, Kim SW, Madelaine J, Molinier O, Özgüroğlu M, Rodríguez Abreu D, Adeniji A, Lorence RM, Voccia I, Chisamore MJ, Riess JW. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer. 2022 Apr;166:107-113. doi:10.1016/j.lungcan.2022.01.023. Epub 2022 Feb 3. PMID:35257949.
Yu HA, Goldberg SB, Le X, Piotrowska Z, Goldman JW, De Langen AJ, Okamoto I, Cho BC, Smith P, Mensi I, Ambrose H, Kraljevic S, Maidment J, Chmielecki J, Li-Sucholeiki X, Doughton G, Patel G, Jewsbury P, Szekeres P, Riess JW. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clin Lung Cancer. 2021 Nov;22(6):601-606. doi:10.1016/j.cllc.2021.06.006. Epub 2021 Jun 25. PMID:34389237.
Riess JW, Reckamp KL, Frankel P, Longmate J, Kelly KA, Gandara DR, Weipert CM, Raymond VM, Keer HN, Mack PC, Newman EM, Lara PN Jr. Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). Clin Lung Cancer. 2021 Nov;22(6):541-548. doi:10.1016/j.cllc.2021.05.001. Epub 2021 May 15. PMID:34140248.
Riess JW, Rahman S, Kian W, Edgerly C, Heilmann AM, Madison R, Ramkissoon SH, Klaitman SS, Chung JH, Trabucco SE, Jin DX, Alexander BM, Klempner SJ, Albacker LA, Frampton GM, Roisman LC, Miller VA, Ross JS, Schrock AB, Gregg JP, Peled N, Sokol ES, Ali SM. Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. Transl Oncol. 2021 Oct;14(10):101184. doi:10.1016/j.tranon.2021.101184. Epub 2021 Jul 29. PMID:34333275.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leal TA, Riess JW, Jensen E, Zhao B, Pietanza MC, Brahmer JR. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021 Jul 20;39(21):2339-2349. doi:10.1200/JCO.21.00174. Epub 2021 Apr 19. PMID:33872070.
Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW Jr, Diehn M, Han SS, Wakelee HA. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. J Thorac Oncol. 2021 Jun;16(6):1030-1041. doi:10.1016/j.jtho.2021.01.1628. Epub 2021 Feb 12. PMID:33588109.
Ji J, Mitra A, Cambridge DR, Reiss JW. Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib. Case Report. 2021 Apr 26;22(6):e851-855. doi:10.1016/j.cllc.2021.04.008.
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet. 2021 Jan;53(1):86-99. doi:10.1038/s41588-020-00750-6. Epub 2021 Jan 7. Erratum in: Nat Genet. 2021 May;53(5):761. PMID:33414553.
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet. 2021 Jan;53(1):86-99. doi:10.1038/s41588-020-00750-6. Epub 2021 Jan 7. Erratum in: Nat Genet. 2021 May;53(5):761. PMID:33414553.